Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $125.1 million.

  • Corcept Therapeutics' Cash & Equivalents fell 885.07% to $125.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.1 million, marking a year-over-year decrease of 885.07%. This contributed to the annual value of $127.7 million for FY2024, which is 581.77% down from last year.
  • Corcept Therapeutics' Cash & Equivalents amounted to $125.1 million in Q3 2025, which was down 885.07% from $102.7 million recorded in Q2 2025.
  • Corcept Therapeutics' Cash & Equivalents' 5-year high stood at $299.9 million during Q1 2023, with a 5-year trough of $35.3 million in Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $102.7 million (2025), whereas its average is $111.3 million.
  • In the last 5 years, Corcept Therapeutics' Cash & Equivalents plummeted by 6296.13% in 2022 and then soared by 38768.46% in 2023.
  • Corcept Therapeutics' Cash & Equivalents (Quarter) stood at $77.6 million in 2021, then fell by 14.54% to $66.3 million in 2022, then soared by 104.36% to $135.6 million in 2023, then dropped by 5.82% to $127.7 million in 2024, then decreased by 1.98% to $125.1 million in 2025.
  • Its Cash & Equivalents stands at $125.1 million for Q3 2025, versus $102.7 million for Q2 2025 and $89.8 million for Q1 2025.